| DOI: 10.29090/psa.2026.04.26.9995 | Pharm Sci Asia 2026; 53(4), 525-533 |
Association between exceeding recommended weight-based doses of first-line antituberculosis drugs and hepatotoxicity during the intensive treatment phase among patients with tuberculosis: A hospital-based case-control studyKhanaphan Hemmarak1, Bhunyabhadh Chaimay2, Somkiattiyos Woradet2*
1 Department of Pharmacy, Sri Naggarindra Hospital, Srinagarindra District, Phatthalung Province, 93000, Thailand
2 Faculty of Health and Sports Science, Phatthalung Campus, Thaksin University, Pa Phayom District, Phatthalung Province, 93210 Thailand
Tuberculosis remains a global health burden. Although first-line antituberculosis drugs are essential for effective treatment, their use may be associated with hepatotoxicity. This study examined the association between the prescribed weight-based doses of isoniazid, rifampicin, pyrazinamide, and ethambutol, and hepatotoxicity during the intensive phase of tuberculosis treatment in routine clinical practice. A hospital-based retrospective case-control study was conducted between January and February 2021 using medical records of patients diagnosed with tuberculosis from 2013 to 2020. A total of 192 subjects were included, comprising 64 cases who developed hepatotoxicity during the intensive phase and 128 matched controls without hepatotoxicity. The exposure variables were the prescribed dose of the first-line antituberculosis drugs isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), and ethambutol (ETB), expressed in mg/kg/day and categorized according to whether they were within or exceeded the recommended weight-based dosing ranges. Multivariable logistic regression was performed to evaluate the association between drug dosage and hepatotoxicity after adjustment for age, sex, baseline body weight, HIV infection, baseline serum total bilirubin, baseline serum albumin, and concomitant hepatotoxic medication use. An INH dose exceeding the recommended weight-based range was significantly associated with higher odds of hepatotoxicity (Adjusted Odds Ratios [AOR] = 2.60, 95% Confidence Interval [CI]: 1.03-6.59). In contrast, doses exceeding the recommended range for RIF (AOR = 1.61, 95%CI: 0.21-12.22), PZA (AOR = 0.61, 95% CI: 0.05-7.58), and ETB (AOR = 1.10, 95% CI: 0.34-3.59) were not significantly associated with hepatotoxicity. These findings indicated that an increased odds of hepatotoxicity during the intensive phase of tuberculosis treatment. Careful verification of weight-based INH dosing and appropriate clinical monitoring should therefore be emphasized in routine tuberculosis care.
Keyword:
Tuberculosis; First-line antituberculosis drugs; Isoniazid; Hepatotoxicity
Download full paper (PDF File size: 493.40 KB.)
|